A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
NCT01330316
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
119
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatitis C
Interventions
DRUG:
BI 201335
DRUG:
PegIFN/RBV
Sponsor
Boehringer Ingelheim